Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

MASTERPLAN : MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

TwoPhase Two

18-75Age 18-75

Pancreas<br/>CancersCancer LocationPancreas
Cancers

Radiotherapy,Surgical,Systemic therapy | Stomach and upper gastrointestinal tractPancreas

Trial Overview Read MoreRead more

This phase II trial is evaluating the effectiveness and safety of chemotherapy (Mfolfirinox) and stereotactic radiotherapy in people with locally advanced pancreatic cancer.
 

This trial is treating patients with pancreatic cancer.

This is a radiation therapy, systemic therapy and surgical trial.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

Cooperative Group

Australasian Gastro-Intestinal Trials Group (AGITG)

Summary

Eligible participants will be randomised on a 2:1 basis based on minimisation and stratification by tumour stage, planned chemotherapy and institution, to one of two arms. Participants in the Experimental Arm will receive chemotherapy (12 week of mFOLFIRINOX and/or 12 additional weeks of gemcitabine/capecitabine), followed by radiation therapy (SBRT) to commence within 3 weeks of completing initial chemotherapy (40 Gray [GY] in 5 fractions over 2 weeks). Eligible participants will receive surgery 6 weeks post-completion of initial surgery. Patients who are not eligible for surgery will continue ongoing chemotherapy. Participants in the Active Comparator Arm will receive chemotherapy (12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine). Eligible participants will receive surgery 6 weeks post-completion of initial surgery. Patients who are not eligible for surgery will continue ongoing chemotherapy.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, William Buckland Radiotherapy Centre
Prahran
Ms Robin Smith
r.smith@alfred.org.au
03 9076 2360

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next